TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Alfuzosin Versus Placebo in Acute Urinary Retention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men with acute urinary retention and catheterized~* Benign hypertrophia of prostate~* Patient is diagnosed in Emergency room or at a acute hospitalization~Exclusion Criteria:~* Known prostate cancer~* Prior urinary retention within 30 days~* Urinary retention occurring in relation to surgery~* Blood in urine~* Difficult or impossible catheterization~* Fever \> 38 degree Celsius~* Decreased kidney function~* Permanent catheter \> 14 days~* Treatment with alfa 1 blocker within 30 days~* Meeting contraindications to treatment with Alfuzosin~* Treatment with other drugs for urinary problems~The above information is not intended to contain all considerations relevant to a patients potential participation in a clinical trial.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Subcutaneous Hydrocortisone Infusion In Addison's Disease and Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- primary Addison's disease in combination with long-standing Type 1 diabetes~Exclusion Criteria:~* cardiovascular disease~* active malignant disease~* pregnant women~* pharmacological treatment with glucocorticoids or drugs that interfere with cortisol metabolism (antiepileptics, rifampicin, St. Johns war, estrogens)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cortef (Type: ACTIVE_COMPARATOR): Treatment A is oral hydrocortisone replacement( Cortef 5 mg)with weight-adjusted doses as suggested by Mah et al , will take 2 months
- Solu-cortef (Type: ACTIVE_COMPARATOR): This is the treatment B by continuous subcutaneous hydrocortisone infusion. Solu-cortef infusion will be given as Solu-Cortef Act-o-Vial 50mg/ml, , produced by Pfizer. Pump designed for subcutaneous insulin infusion can be used for subcutaneous administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pain Perception in Suicidal Behavior Vulnerability

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* aged by 18 years old~* came from West Europe, excepted Basque and Sardinian (because of genetics analysis)~* main diagnosis of major depressive episode (DSM V criteria)~* not having take antalgics in the 24 hours before assessment~* received a minimal psychotrope treatment (clinician evaluation)~* Able to understand nature, aims, methodology of the study~* Agree to cooperate in clinical and biological assessment~* Having signed informed consent~Specific inclusion criteria :~81 recent suicide attempters (being hospitalised for suicidal attempts and having realised a suicide attempts 8 days before inclusion) 81 former suicide attempters (having realised in his lifetime a suicide attempt, one month before inclusion)~Exclusion criteria:~* Current diagnosis of manic, hypomanic or alcohol dependance or substance abuse in the last 6 months, or diagnosis of schizophrenia or schizoaffective disorder in his lifetime~* Current algic and chronic neurologic disease~* Current or actual treatment by tricyclic antidepressant and Serotonin and norepinephrine reuptake inhibitors(SNRIs)~* Pregnancy~* Patients on protective measure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study participant (Type: OTHER): All the participants performed blood sample for genetic purpose, psychiatric assessment and pain investigation:~* 81 depressed patients admitted after a recent suicidal act (\<8 days)~* 81 depressed subjects with a past history of suicidal act (\>1month)~* 80 depressed subjects without any personal history of suicidal behaviour

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of SMR Neurofeedback on Insomnia in Patients With Benign Brain Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed as primary benign brain tumors such as: meningioma, schwannoma, pituitary tumor, craniopharyngioma according to the results of pathological tissue sections and has completed treatment such as : Surgery, radiation therapy, etc. for at least 7 days.~* Aged from 20 to 65 years old and conscious, able to communicate in Mandarin and Taiwanese.~* Cognitive ability sufficient to complete the questionnaire.~* Complaints of insomnia and ISI score ≥ 8~Exclusion Criteria:~* Long-term shift workers one month before the included study.~* Pregnant women.~* Jet lag workers, such as airline workers.~* Vision, hearing or motor dysfunction is severe enough to affect the participating researcher.~* Preoperative diagnosis of insomnia or long-term use of sleep aids or psychiatric drugs.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- sensorimotor rhythm neurofeedback training (Type: EXPERIMENTAL): Sensory motor rhythm neurofeedback: The subjects will perform 60 minutes per week for 10 weeks, with a total training time of 600 minutes. The intervention in this trial lasts for 10 weeks (1 time/week), with the goal of improving sensory motor rhythm. Since this training uses visual and auditory feedback, if patients are assigned to this group, they will be ask to wear an EEG cap with 19 electrodes. They can take a relaxed sitting posture and choose animations (e.g., puzzles, mazes, and other feedback content), and then focus on computer screen animation for training, each training time is approximately 60 minutes.
- control group (Type: NO_INTERVENTION): Patient should maintain their usual activity and treatment. Research assistants will weekly contact them to confirm their compliance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin Resistance and Sleep Apnea in Type-2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged \> 18 years old~* With Type 2 diabetes~* Stable Atherothrombosis for more than 3 months~* Using aspirin for more than 10 days or without aspirin (in this last case, they will do only the observational study.)~* Without any modification in their treatments for 10 days~* Ambulatory patient~* Without any cardiovascular event or inflammatory disease for 3 months before inclusion~Exclusion Criteria:~* Pregnant women~* Other active clinically significant illness, including unstable cardiovascular, or neoplasia which could interfere with the study conduct or counterindicate the study treatments or place the patient at risk during the trial or compromise the study participation~* Patients participating in an other study~* Patient without any medical care insurance~* Any treatment that could interfere with aspirin~* Previous treatment by CPAP

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CPAP (Type: ACTIVE_COMPARATOR): This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.~Other Name: positive airway pressure
- Sham-CPAP (Type: PLACEBO_COMPARATOR): This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women requesting contraception~* 16-35 years old~* Cohort 36-45 years old~* Sexually active~Exclusion Criteria:~* Currently pregnant, pregnant within 4 weeks prior to study entry or planning pregnancy within 24 months of study entry~* Currently breastfeeding~* Current persistent, abnormal vaginal bleeding

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- LNG20 (16-35 Year Olds) (Type: EXPERIMENTAL): LNG20 levonorgestrel-releasing intrauterine system in subjects 16-35 years of age
- Mirena (Type: ACTIVE_COMPARATOR): Levonorgestrel-releasing intrauterine system for contraception
- LNG20 (36-45 Year Olds) (Type: EXPERIMENTAL): LNG20 levonorgestrel-releasing intrauterine system in subjects 36-45 years of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of SOBI002 in Healthy Volunteers Following Single and Repeated Administration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females of non-childbearing potential or males~* 18 to 45 years of age~* Judged by the Principal Investigator to be healthy on the basis of medical history and a pre-study physical examination including 12-lead electrocardiogram (ECG), 24-hour Holter ECG, vital signs and blood and urine laboratory assessments.~Exclusion Criteria:~* Females of childbearing potential~* Clinically significant disease~* Clinically significant abnormal laboratory, ECG, vital signs or other safety findings as determined by medical history, physical examination or other evaluations conducted at screening or on admission.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- SOBI002 (Type: EXPERIMENTAL): Single and repeated administration of different doses of test product
- placebo (Type: PLACEBO_COMPARATOR): Single and repeated administration of placebo comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: S9624 Ifosfamide in Treating Patients With Meningeal Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven recurrent or unresectable:~* Malignant meningioma~* Intracranial hemangiopericytoma~* Primary central nervous system sarcoma, including:~* Fibrosarcoma~* Rhabdomyosarcoma~* Chondrosarcoma~* Leiomyosarcoma~* Measurable or evaluable disease on CT or MRI scan~* Persistent disease following biopsy or incomplete resection OR~* Recurrent disease following complete resection~* No benign meningioma~* No prior or current systemic sarcoma~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* SWOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 3,000/mm\^3~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Not specified~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No myocardial infarction within the past 3 months~* No active angina~* No unstable heart rhythms~* No congestive heart failure~Other:~* HIV negative~* No allergy to study drugs~* No serious concurrent medical or psychiatric illness~* No uncontrolled peptic ulcer disease~* No prior malignancy within past 5 years except adequately treated:~* Basal or squamous cell carcinoma of the skin~* Carcinoma in situ of the cervix~* Not pregnant or nursing~* Effective contraception required of fertile patients~PRIOR CONCURRENT THERAPY:~* Recovered from toxic effects of prior therapy and/or from postoperative complications~Biologic therapy:~* Not specified~Chemotherapy:~* No prior ifosfamide~* No other concurrent chemotherapy~Endocrine therapy:~* No concurrent hormonal therapy (except estrogen replacement therapy)~* Corticosteroids allowed if dose is stable or decreasing~Radiotherapy:~* At least 4 weeks since prior radiotherapy~* Progressive disease following radiation required~* No concurrent radiotherapy~Surgery:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ifosfamide (Type: EXPERIMENTAL): ifosfamide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients with pulmonary arterial hypertension (PAH) as defines by a mean pulmonary artery pressure (PAP) of 25 mmHg or greater by cardiac catheterization within the previous 12 months AND/OR Patients with chronic lung disease with severe impairment of gas exchange unresponsive to conventional medical management.~* If patient is receiving prostacyclin infusion treatment it must have been started at least one month prior to starting INO therapy. Patients will not be withdrawn from the study if started on other medications for treatment of pulmonary hypertension.~* Ability to establish a clinical investigator and a drug shipment site in the local area.~Exclusion Criteria:~* The Principal Investigator has determined that the patient and/or caregiver is/are unable to manage safe administration of home nitric oxide therapy and maintain appropriate drug accountability and storage.~* Women who are pregnant or nursing.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Negative Pressure Wound Therapy: Are All Systems Alike?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized adults requiring negative pressure dressings.~Exclusion Criteria:~* Comatose~* Mentally obtunded~* Documented chronic psychiatric illness or any documented dementia significant enough to notably impair cognitive function~* Presence of Manufacturer's contraindications~* Malignancy in wound~* Untreated osteomyelitis~* Unexplored fistula~* Necrotic tissue~* Exposed blood vessels or organs~* Untreated malnutrition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): KCI VAC type negative pressure wound therapy device
- 2 (Type: EXPERIMENTAL): Versatile One (EZCare) negative wound therapy device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females who are greater than or equal to 21 years of age,~* Subjects with a ASCUS (Atypical Squamous Cells - Undetermined Significance) cytology result,~* Females who provide informed consent~Exclusion Criteria:~* Known pregnant~* Prior complete or partial hysterectomy involving removal of cervix~* Conization, LEEP, cervical laser surgery or cryosurgery on the cervix has been performed in the last twelve months~* Colposcopy clinic referral patients

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- BD HPV assay on Viper LT (Type: EXPERIMENTAL): The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.~Device: BD HPV assay on Viper LT The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test. Colposcopy/biopsy will be performed on all subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevalence of Sleep Disordered Breathing

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age equal to or greater than 18 years at time of consent~* Written informed consent~* Patients admitted to the intensive care unit if able to remove oxygen~* Patients admitted to telemetry and step-down floor that will not require oxygen~* Primary diagnosis (any of the following)~* Un-stable angina~* Acute myocardial infarction~* Congestive heart failure~Exclusion Criteria:~* Previously diagnosed sleep disordered breathing~* Inability to consent~* Pregnancy~* Intubation (no longer excluded after extubation)~* Oxygen therapy (no longer excluded after therapy ends)~* End-Stage renal disease~* End-Stage liver disease~* Terminal disorders other than cardiac~* Severe scoliosis~* Cervical spinal cord injuries~* Neuromuscular disorders~* Severe COPD as defined by prescription of home oxygen therapy~* Other unsuitable circumstances

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acute coronary conditions (Type: None): Patients hospitalized with the following conditions~* Unstable angina~* Acute myocardial infarction~* Congestive heart failure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* female patients, \>=18 years of age;~* HER2-negative, locally advanced (stage II or III) or inflammatory cancer of the breast;~* ECOG performance status 0-1.~Exclusion Criteria:~* metastatic disease (stage IV);~* previous treatment for breast cancer;~* evidence of CNS metastasis;~* current or recent (within 10 days of first dose of Avastin) use of aspirin (\>325mg/day) NSAIDs or full dose anticoagulants for therapeutic purposes;~* clinically significant cardiovascular disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues